Bigul

Q2FY24 Quarterly Result Announced for Zydus Wellness Ltd.

Packaged Foods company Zydus Wellness announced Q2FY24 results: 1. Net Sales Performance: For the second quarter ended September 30, 2023, Zydus Wellness reported consolidated net sales of Rs 438 crore. 2. Key Brand Performance: Several key brands, including Glucon-D, Everyuth, Nycil, and Nutralite, recorded a strong performance during the quarter. These brands have consistently delivered positive results. 3. Market Leadership: The Sugarfree brand maintained its leadership in its category with a market share of 96.1%. Glucon-D also continued to dominate the market with a market share of 60.0%. These brands have established themselves as market leaders. 4. Digital Engagement: The company actively promoted Glucon-D's new variants of mango flavor and sachets through digital engagement with consumers. This strategy has helped in creating awareness and driving sales. 5. Volume Growth: Complan, the company's health food drink brand, continued to register volume offtake growth ahead of the category. It has gained a market share of 4.4% as of September 2023. This indicates increased consumer preference for the brand. 6. Strong Performance in Personal Care: In the personal care segment, Zydus Wellness brands Nycil and Everyuth outperformed their respective categories. Nycil maintained its number one position in the prickly heat powder category with a market share of 35.2% and registered double-digit growth. Everyuth Scrub and Everyuth Peel off also held their number one positions in their respective categories, displaying consistent consumer demand. Result PDF
06-11-2023
Bigul

ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release on unaudited results for the quarter and half year ended on September 30, 2023
06-11-2023
Bigul

Zydus receives FDA approval for Zituvimettm, shares fall

The Zituvimettm approval provides an affordable treatment option for healthcare systems, says Zydus Lifesciences MD Dr Sharvil Patel
06-11-2023
Bigul

ZYDUS WELLNESS LTD.-$ - 531335 - Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2023

Unaudited financial results for the quarter and half year ended on September 30, 2023
06-11-2023
Bigul

Zydus Lifesciences to co-promote Guardant Health biopsy tests in India and Nepal

The Zydus-Guardant joint promotion would help advance precision medicine and improve patient outcomes in the region'
02-11-2023
Bigul

ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Change in Directorate

Cessation of Mr. Savyasachi Sengupta as an Independent Director of the Company due to completion of term
01-11-2023
Bigul

Zydus Lifesciences acquires UK's LiqMeds Group for 68 million

The transaction gives Zydus end-to-end capabilities to target markets in Europe and the US
31-10-2023
Bigul

Zydus Lifesciences partners with Sun Pharma, shares up

Sun Pharma will market Desidustat under the brand name RYTSTAT, complementing Zydus' own marketing efforts under the brand name Oxemia
30-10-2023
Next Page
Close

Let's Open Free Demat Account